{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:30:24Z","timestamp":1768890624908,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Chronic kidney disease (CKD) attributed to diabetes occurs in 20%\u201340% of patients with diabetes mellitus. Diabetic kidney disease (DKD) is recognized as the most common cause of end-stage kidney disease in the USA and most Western countries. For quite some time, it has been recognized that treatments based on inhibition of the renin-angiotensin system (RAS) can reduce the rates of cardiovascular morbidity and mortality in patients with DKD. Recently however, several novel agents, namely sodium-glucose co-transporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors and glucagon-like peptide-1 receptor agonists, were demonstrated to not only improve glycemic control but also to improve cardiovascular and renal outcomes. Another agent, a nonsteroidal mineralocorticoid antagonist, has also been shown to have cardiorenal benefits in patients with DKD. With such new developments, one would expect that it would eventually translate into further slowing CKD progression in the DKD population, provided that patients are diagnosed appropriately and in a timely manner. In this study, the authors attempt to investigate real-world data, looking at how well providers are establishing the diagnosis of DKD and its potential implications.<\/jats:p>","DOI":"10.1093\/ckj\/sfac163","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T12:22:39Z","timestamp":1656418959000},"page":"1797-1799","source":"Crossref","is-referenced-by-count":11,"title":["Diagnosis 101: diabetic kidney disease"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-5478","authenticated-orcid":false,"given":"Edgar V","family":"Lerma","sequence":"first","affiliation":[{"name":"Section of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine\/ Associates in Nephrology, S.C. , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"2022092209482663700_bib1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"2022092209482663700_bib2","article-title":"2020 USRDS Annual Data Report: epidemiology of kidney disease in the United States","author":"United States Renal Data System","year":"2020"},{"key":"2022092209482663700_bib3","article-title":"Screening, early diagnosis, genetic markers and predictors of progression","volume-title":"Diabetic Kidney Disease","author":"Tuazon","edition":"2nd edition."},{"key":"2022092209482663700_bib4","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.2337\/dc20-S011","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2022092209482663700_bib5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","article-title":"KDOQI Clinical Practice Guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"National Kidney Foundation","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2022092209482663700_bib6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","article-title":"Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure","volume":"309","author":"Hannedouche","year":"1994","journal-title":"BMJ"},{"key":"2022092209482663700_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes, Obes Metab"},{"key":"2022092209482663700_bib15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2022092209482663700_bib17","first-page":"28","article-title":"Slowing diabetic kidney disease progression: where do we stand today?","volume-title":"Chronic Kidney Disease and Type 2 Diabetes","author":"Naaman","year":"2021"},{"key":"2022092209482663700_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfac100","article-title":"The hidden diabetic kidney disease in a university hospital-based population: as real world data analysis","volume-title":"Clin Kidney J","author":"Marques","year":"2022"},{"key":"2022092209482663700_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2369-14-46","article-title":"Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 Study","volume":"14","author":"Rodriguez-Poncelas","year":"2013","journal-title":"BMC Nephrol"},{"key":"2022092209482663700_bib20","doi-asserted-by":"crossref","first-page":"e110535","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PLoS One"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac163\/45021273\/sfac163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/10\/1797\/45972175\/sfac163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/10\/1797\/45972175\/sfac163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T09:50:26Z","timestamp":1663840226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/10\/1797\/6619075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,6,28]]},"published-print":{"date-parts":[[2022,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac163","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,6,28]]}}}